Lukas Biomedical Inc.
Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distribute… Read more
Lukas Biomedical Inc. (6814) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.138x
Based on the latest financial reports, Lukas Biomedical Inc. (6814) has a cash flow conversion efficiency ratio of -0.138x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-39.13 Million) by net assets (NT$283.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Lukas Biomedical Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Lukas Biomedical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Lukas Biomedical Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lukas Biomedical Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ArborGen Holdings Limited
PINK:RUBNF
|
-0.051x |
|
Cords Cable Industries Limited
NSE:CORDSCABLE
|
0.141x |
|
Predictive Oncology Inc
NASDAQ:POAI
|
0.021x |
|
Central China Real Estate Limited
PINK:CNLLF
|
-0.352x |
|
Century Extrusions Limited
NSE:CENTEXT
|
0.095x |
|
NEXTEDIA S.A. EO -10
F:9KA
|
N/A |
|
Superlon Holdings Bhd
KLSE:7235
|
0.030x |
|
Quartz Mountain Resources Ltd
PINK:QZMRF
|
-0.274x |
Annual Cash Flow Conversion Efficiency for Lukas Biomedical Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Lukas Biomedical Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$325.82 Million | NT$-70.53 Million | -0.216x | -416.25% |
| 2023-12-31 | NT$280.13 Million | NT$-11.75 Million | -0.042x | -84.68% |
| 2022-12-31 | NT$327.49 Million | NT$-7.44 Million | -0.023x | +59.71% |
| 2021-12-31 | NT$286.68 Million | NT$-16.16 Million | -0.056x | -156.46% |
| 2020-12-31 | NT$290.88 Million | NT$29.03 Million | 0.100x | -49.05% |
| 2019-12-31 | NT$301.42 Million | NT$59.05 Million | 0.196x | -- |